Page 165 - 2019_02-Haematologica-web

Refining prognosis in early-stage CLL
Italian external and multicentric validation of the MD Anderson Cancer Center nomogram and prognostic index for chronic lymphocytic leukaemia patients: analysis of 1502 cases. Br J Haematol. 2014;167(2):224-232.
6. Haferlach C, Dicker F, Weiss T, et al. Toward a comprehensive prognostic scor- ing system in chronic lymphocytic leukemia based on a combination of genet- ic parameters. Genes Chromosomes Cancer. 2010;49(9):851-859.
7. International CLLIPIwg. An international prognostic index for patients with chronic lymphocytic leukaemia (CLL-IPI): a meta- analysis of individual patient data. Lancet Oncol. 2016;17(6):779-790.
8. Morabito F, Cutrona G, Gentile M, et al. Definition of progression risk based on combinations of cellular and molecular markers in patients with Binet stage A chronic lymphocytic leukaemia. Br J Haematol. 2009;146(1):44-53.
9. Oscier DG, Gardiner AC, Mould SJ, et al. Multivariate analysis of prognostic factors in CLL: clinical stage, IGVH gene mutation- al status, and loss or mutation of the p53 gene are independent prognostic factors. Blood. 2002;100(4):1177-1184.
10. Rossi D, Rasi S, Spina V, et al. Integrated mutational and cytogenetic analysis identi- fies new prognostic subgroups in chronic lymphocytic leukemia. Blood. 2013; 121(8):1403-1412.
11. Shanafelt TD, Jenkins G, Call TG, et al. Validation of a new prognostic index for patients with chronic lymphocytic leukemia. Cancer. 2009;115(2):363-372.
12. Wierda WG, O'Brien S, Wang X, et al. Prognostic nomogram and index for overall survival in previously untreated patients with chronic lymphocytic leukemia. Blood. 2007;109(11):4679-4685.
13. Baliakas P, Mattsson M, Stamatopoulos K, Rosenquist R. Prognostic indices in chronic lymphocytic leukaemia: where do we stand how do we proceed? J Intern Med. 2016;279(4):347-357.
14. Fabbri G, Dalla-Favera R. The molecular pathogenesis of chronic lymphocytic leukaemia. Nat Rev Cancer. 2016; 16(3): 145-162.
15. Sutton LA, Rosenquist R. Deciphering the molecular landscape in chronic lymphocyt- ic leukemia: time frame of disease evolu- tion. Haematologica. 2015;100(1):7-16.
16. Sutton LA, Rosenquist R. The complex interplay between cell-intrinsic and cell- extrinsic factors driving the evolution of chronic lymphocytic leukemia. Semin Cancer Biol. 2015;34:22-35.
17. Landau DA, Carter SL, Stojanov P, et al. Evolution and impact of subclonal muta- tions in chronic lymphocytic leukemia. Cell. 2013;152(4):714-726.
18. Landau DA, Tausch E, Taylor-Weiner AN, et al. Mutations driving CLL and their evo- lution in progression and relapse. Nature. 2015;526(7574):525-530.
19. Stevenson FK, Caligaris-Cappio F. Chronic lymphocytic leukemia: revelations from the B-cell receptor. Blood. 2004; 103(12):4389-4395.
20. Damle RN, Wasil T, Fais F, et al. Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lym- phocytic leukemia. Blood. 1999;94(6):1840- 1847.
21. Hamblin TJ, Davis Z, Gardiner A, Oscier
DG, Stevenson FK. Unmutated Ig V(H) genes are associated with a more aggres- sive form of chronic lymphocytic leukemia. Blood. 1999;94(6):1848-1854.
22. Fischer K, Bahlo J, Fink AM, et al. Long- term remissions after FCR chemoim- munotherapy in previously untreated patients with CLL: updated results of the CLL8 trial. Blood. 2016;127(2):208-215.
23. Rossi D, Terzi-di-Bergamo L, De Paoli L, et al. Molecular prediction of durable remis- sion after first-line fludarabine-cyclophos- phamide-rituximab in chronic lymphocyt- ic leukemia. Blood. 2015;126(16):1921- 1924.
24. Thompson PA, Tam CS, O'Brien SM, et al. Fludarabine, cyclophosphamide, and ritux- imab treatment achieves long-term disease- free survival in IGHV-mutated chronic lym- phocytic leukemia. Blood. 2016;127(3):303- 309.
25. Kulis M, Heath S, Bibikova M, et al. Epigenomic analysis detects widespread gene-body DNA hypomethylation in chronic lymphocytic leukemia. Nat Genet. 2012;44(11):1236-1242.
26. Marincevic M, Cahill N, Gunnarsson R, et al. High-density screening reveals a differ- ent spectrum of genomic aberrations in chronic lymphocytic leukemia patients with 'stereotyped' IGHV3-21 and IGHV4- 34 B-cell receptors. Haematologica. 2010; 95(9):1519-1525.
27. Ntoufa S, Vardi A, Papakonstantinou N, et al. Distinct innate immunity pathways to activation and tolerance in subgroups of chronic lymphocytic leukemia with dis- tinct immunoglobulin receptors. Mol Med. 2012;18:1281-1291.
28. Baliakas P, Hadzidimitriou A, Sutton LA, et al. Clinical effect of stereotyped B-cell receptor immunoglobulins in chronic lym- phocytic leukaemia: a retrospective multi- centre study. Lancet Haematology. 2014; 1(2):74-84.
29. Agathangelidis A, Vardi A, Baliakas P, Stamatopoulos K. Stereotyped B-cell recep- tors in chronic lymphocytic leukemia. Leuk Lymphoma. 2014;55(10):2252-2261.
30. B aliakas P, Agathangelidis A, Hadzidimitriou A, et al. Not all IGHV3-21 chronic lymphocytic leukemias are equal: prognostic considerations. Blood. 2015; 125(5):856-859.
31. Xochelli A, Baliakas P, Kavakiotis I, et al. Chronic Lymphocytic Leukemia with Mutated IGHV4-34 Receptors: Shared and Distinct Immunogenetic Features and Clinical Outcomes. Clin Cancer Res. 2017; 23(17):5292-5301.
32. Jeromin S, Haferlach C, Dicker F, Alpermann T, Haferlach T, Kern W. Differences in prognosis of stereotyped IGHV3-21 chronic lymphocytic leukaemia according to additional molecular and cyto- genetic aberrations. Leukemia. 2016;30(11):2251-2253.
33. Baliakas P, Mattsson M, Hadzidimitriou A, et al. No improvement in long-term sur- vival over time for chronic lymphocytic leukemia patients in stereotyped subsets #1 and #2 treated with chemo(immuno)thera- py. Haematologica. 2018;103(4):e158-e161.
34. Baliakas P, Hadzidimitriou A, Sutton LA, et al. Recurrent mutations refine prognosis in chronic lymphocytic leukemia. Leukemia. 2015;29(2):329-336.
35. Jeromin S, Weissmann S, Haferlach C, et al. SF3B1 mutations correlated to cytogenetics
and mutations in NOTCH1, FBXW7, MYD88, XPO1 and TP53 in 1160 untreated CLL patients. Leukemia. 2014;28(1):108-117.
36. Baliakas P, Hadzidimitriou A, Agathangelidis A, et al. Prognostic rele- vance of MYD88 mutations in CLL: the jury is still out. Blood. 2015;126(8):1043- 1044.
37. Hallek M, Cheson BD, Catovsky D, et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood. 2008; 111(12):5446-5456.
38. Dohner H, Stilgenbauer S, Benner A, et al. Genomic aberrations and survival in chron- ic lymphocytic leukemia. N Engl J Med. 2000;343(26):1910-1916.
39. Agathangelidis A, Darzentas N, Hadzidimitriou A, et al. Stereotyped B-cell receptors in one-third of chronic lympho- cytic leukemia: a molecular classification with implications for targeted therapies. Blood. 2012;119(19):4467-4475.
40. Harrell FE, Jr., Lee KL, Mark DB. Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat Med. 1996;15(4):361-387.
41. Hothorn T, Hornik K, Zeileis A. Unbaised Recursive Partitioning: A Conditional Inference Framework. Journal of Computational and Graphical Statistics. 2006;15(3):651-674.
42. Hallek M. Chronic lymphocytic leukemia: 2015 Update on diagnosis, risk stratifica- tion, and treatment. Am J Hematol. 2015;90(5):446-460.
43. Ljungstrom V, Cortese D, Young E, et al. Whole-exome sequencing in relapsing chronic lymphocytic leukemia: clinical impact of recurrent RPS15 mutations. Blood. 2016;127(8):1007-1016.
44. Rossi D, Spina V, Bomben R, et al. Association between molecular lesions and specific B-cell receptor subsets in chronic lymphocytic leukemia. Blood. 2013; 121(24):4902-4905.
45. Sutton LA, Young E, Baliakas P, et al. Different spectra of recurrent gene mutations in subsets of chronic lymphocytic leukemia harboring stereotyped B-cell receptors. Haematologica. 2016;101(8):959-967.
46. Byrd JC, Furman RR, Coutre SE, et al. Three-year follow-up of treatment-naive and previously treated patients with CLL and SLL receiving single-agent ibrutinib. Blood. 2015;125(16):2497-2506.
47. Roberts AW, Davids MS, Pagel JM, et al. Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia. N Engl J Med. 2016;374(4):311-322.
48. Lamanna N, O'Brien S. Novel agents in chronic lymphocytic leukemia. Hematology Am Soc Hematol Educ Program. 2016;2016(1):137-145.
49. Bystry V, Agathangelidis A, Bikos V, et al. ARResT/AssignSubsets: a novel application for robust subclassification of chronic lym- phocytic leukemia based on B cell receptor IG stereotypy. Bioinformatics. 2015; 31(23):3844-3846.
50. Karube K, Enjuanes A, Dlouhy I, et al. Integrating genomic alterations in diffuse large B-cell lymphoma identifies new rele- vant pathways and potential therapeutic targets. Leukemia. 2018;32(3):675-684.
haematologica | 2019; 104(2)
369